secwatch / observer
8-K filed May 2, 2025, 7:59 PM ET CIK 0001289850
M&A confidence high sentiment neutral materiality 0.90

NeuroMetrix, Inc.: M&A transaction — NeuroMetrix completes merger with electroCore; shareholders receive $4.49/share plus CVRs

NeuroMetrix, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joshua Horowitz

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
Departed

David Van Avermaete

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
Departed

Shai N. Gozani

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
Appointed

Dan Goldberger

Chief Executive Officer
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
Dan Goldberger became the Chief Executive Officer of the Surviving Corporation
Appointed

Dan Goldberger

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
At the Effective Time, in connection with the consummation of the Merger, and pursuant to the Merger Agreement each of Dan Goldberger and Joshua Lev (the directors of Merger Sub immediately prior to the Effective Time) became the directors of the Surviving Corporation in lieu of the Company’s existing directors.
Appointed

Joshua Lev

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
At the Effective Time, in connection with the consummation of the Merger, and pursuant to the Merger Agreement each of Dan Goldberger and Joshua Lev (the directors of Merger Sub immediately prior to the Effective Time) became the directors of the Surviving Corporation in lieu of the Company’s existing directors.
Appointed

Joshua Lev

Chief Financial Officer
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
Joshua Lev became the Chief Financial Officer of the Surviving Corporation
Departed

Nancy E. Katz

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
Departed

David E. Goodman

Director
NeuroMetrix, Inc.
Filed
May 2, 2025, 7:59 PM ET
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joshua Horowitz departed as Director at NeuroMetrix, Inc..

Action
ceased
Role
Director
Exact text from the filing
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

David Van Avermaete departed as Director at NeuroMetrix, Inc..

Action
ceased
Role
Director
Exact text from the filing
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Shai N. Gozani departed as Director at NeuroMetrix, Inc..

Action
ceased
Role
Director
Exact text from the filing
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Dan Goldberger was appointed as Chief Executive Officer at NeuroMetrix, Inc..

Action
became
Role
Chief Executive Officer
Exact text from the filing
Dan Goldberger became the Chief Executive Officer of the Surviving Corporation
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Dan Goldberger was appointed as Director at NeuroMetrix, Inc..

Action
became
Role
Director
Exact text from the filing
At the Effective Time, in connection with the consummation of the Merger, and pursuant to the Merger Agreement each of Dan Goldberger and Joshua Lev (the directors of Merger Sub immediately prior to the Effective Time) became the directors of the Surviving Corporation in lieu of the Company’s existing directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Joshua Lev was appointed as Director at NeuroMetrix, Inc..

Action
became
Role
Director
Exact text from the filing
At the Effective Time, in connection with the consummation of the Merger, and pursuant to the Merger Agreement each of Dan Goldberger and Joshua Lev (the directors of Merger Sub immediately prior to the Effective Time) became the directors of the Surviving Corporation in lieu of the Company’s existing directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Joshua Lev was appointed as Chief Financial Officer at NeuroMetrix, Inc..

Action
became
Role
Chief Financial Officer
Exact text from the filing
Joshua Lev became the Chief Financial Officer of the Surviving Corporation
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Nancy E. Katz departed as Director at NeuroMetrix, Inc..

Action
ceased
Role
Director
Exact text from the filing
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

David E. Goodman departed as Director at NeuroMetrix, Inc..

Action
ceased
Role
Director
Exact text from the filing
In connection with the consummation of the Merger, each of Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.4

NeuroMetrix, Inc.: The Surviving Corporation adopted the Fourth Amended and Restated Certificate of Incorporation in connection with the Merger.

Change
charter amendment
Exact text from the filing
At the Effective Time and in connection with the Merger, the Surviving Corporation adopted the Fourth Amended and Restated Certificate of Incorporation, in the form attached hereto as Exhibit 3.1(the “ Amended and Restated Certificate ”).
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.4

NeuroMetrix, Inc.: The Surviving Corporation adopted Amended and Restated Bylaws in connection with the Merger.

Change
bylaw amendment
Exact text from the filing
At the Effective Time and in connection with the Merger, the Surviving Corporation adopted the Amended and Restated Bylaws, in the form attached hereto as Exhibit 3.2 (the “ Amended and Restated Bylaws ”).
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NeuroMetrix, Inc. underwent a change of control involving electroCore, Inc. for $4.49 per share in cash plus one contingent value right (closed 2025-05-01).

Action
change of control
Counterparty
electroCore, Inc.
Consideration
$4.49 per share in cash plus one contingent value right
Closing
2025-05-01
Exact text from the filing
the “ Merger Consideration ”). In accordance with the Merger Agreement, the Per Share Cash Consideration was determined by the Company and Parent to be in the amount of $4.49 per share of Company Common Stock. Each share of preferred stock, par value $0.001 per share, of the Company (the “ Company Preferred Stock ”) outstanding immediately prior to the
View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR
accession 0001641172-25-008179
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.